Savara Inc.
NASDAQ:SVRA · NASDAQ Global Select
+$0.03 today
Vol 3.57M · Avg 1.53M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-58.5%
avg -53.7%
ROIC
-53.0%
avg -45.9%
ROA
-46.9%
avg -41.2%
Analysis
ROA is currently the strongest return metric at -46.9% versus its period average of -41.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Matthew Pauls | Chairman & Chief Executive Officer | $975,000.00 | — | 55 | $1.19M | 0.58% |
Yasmine Wasfi | Chief Medical Officer | $681,578.00 | — | — | $168,008.00 | 0.08% |
David L. Lowrance | Chief Financial & Administrative Officer and Secretary | $665,625.00 | — | 58 | $552,550.00 | 0.27% |
Robert Lutz | Chief Operating Officer | $665,625.00 | — | 57 | $293,977.00 | 0.14% |
Brian Robinson | Executive Vice President of Global Medical Affairs | — | — | — | $2.37M | 1.16% |
Charles LaPree | Executive Vice President & Head of Global Regulatory Affairs | — | — | — | — | — |
Anne Erickson | Chief Business & Corporate Affairs Officer | — | — | 54 | $371,712.00 | 0.18% |
Kate McCabe | Chief Legal Officer | — | — | 40 | $519,232.00 | 0.25% |
Brian Maurer | Head of Clinical Operations | — | — | — | $2.37M | 1.16% |
Siddharth J. Advant | Executive Vice President of Global Technical Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$121,220.00
Net Sentiment
$121,220.00
Net selling
Most Active
RAMSAY DAVID A
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $121,220.00 over the last 12 months. That adds up to net selling of $121,220.00. RAMSAY DAVID A was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +192.8% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +192.8% (15yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.55B
Nanobiotix S.A.
NASDAQ:NBTX
$1.78B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.67B
GH Research PLC
NASDAQ:GHRS
$1.48B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.25B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.12B
Kura Oncology, Inc.
NASDAQ:KURA
$854.90M
Geron Corporation
NASDAQ:GERN
$821.15M
Rezolute, Inc.
NASDAQ:RZLT
$487.72M
ProKidney Corp.
NASDAQ:PROK
$261.50M
Who manages SVRA?
Savara Inc. (SVRA) lists 10 active executives. The top listed executive is Brian Robinson, Executive Vice President of Global Medical Affairs.
Are SVRA insiders buying or selling?
Recent insider activity shows net buying of $15.75M.
Explore More
Continue the stock analysis
Jump to another research area for this company.